LPCN vs. HLVX, VOR, MNOV, PYXS, PWUP, DBVT, VIGL, ALGS, TARA, and CTOR
Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include HilleVax (HLVX), Vor Biopharma (VOR), MediciNova (MNOV), Pyxis Oncology (PYXS), PowerUp Acquisition (PWUP), DBV Technologies (DBVT), Vigil Neuroscience (VIGL), Aligos Therapeutics (ALGS), Protara Therapeutics (TARA), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry.
Lipocine vs.
HilleVax (NASDAQ:HLVX) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, community ranking, media sentiment and institutional ownership.
HilleVax has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.
Lipocine has higher revenue and earnings than HilleVax. Lipocine is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.
86.4% of HilleVax shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 71.1% of HilleVax shares are owned by insiders. Comparatively, 6.1% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, HilleVax and HilleVax both had 2 articles in the media. Lipocine's average media sentiment score of 0.94 beat HilleVax's score of 0.43 indicating that Lipocine is being referred to more favorably in the news media.
Lipocine's return on equity of -19.17% beat HilleVax's return on equity.
Lipocine received 337 more outperform votes than HilleVax when rated by MarketBeat users. Likewise, 68.58% of users gave Lipocine an outperform vote while only 58.82% of users gave HilleVax an outperform vote.
HilleVax presently has a consensus price target of $3.00, suggesting a potential upside of 52.28%. Lipocine has a consensus price target of $10.00, suggesting a potential upside of 131.48%. Given Lipocine's stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than HilleVax.
Summary
Lipocine beats HilleVax on 12 of the 15 factors compared between the two stocks.
Get Lipocine News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipocine Competitors List
Related Companies and Tools
This page (NASDAQ:LPCN) was last updated on 2/1/2025 by MarketBeat.com Staff
Free LPCN Stock Alerts